Clinical study of apatinib combined with SOX as the first-line treatment for liver metastases of gastric cancer

Abstract

Objective To observe the clinical efficacy and safety of Apatinib combined with SOX as first-line treatment for liver metastases of gastric cancer. Methods In this study, 29 patients with liver metastases from gastric cancer treated in Chifeng Hospital from September 2015 to September 2017 were selected, including 500 mg of apatinib once a day, 40-60 mg of S1 twice a day orally from the first day to the fourteenth day after breakfast, and 130 mg/m2 of oxaliplatin for 2 hours of intravenous injection on the first day. Twenty-one days was a cycle. The efficacy and adverse reactions were evaluated after two cycles. Results The curative effect was evaluated in 29 cases, including complete remission (CR) in 0 cases, partial remission (PR) in 15 cases, stable condition (SD) in 8 cases, disease progression (PD) in 6 cases, objective response rate (RR) in 51.7% and disease control rate (DCR) in 79.3%. Median time of disease progression (mTTP) and median survival time were 4.7 months and 10.6 months respectively. One year survival rate was 30.6% and quality of life (QOL) improvement stability rate was 75.9%. The side effects were mainly hypertension, proteinuria, bone marrow suppression, hand-foot syndrome, fatigue, neurotoxicity and diarrhea. Conclusions Apatinib combined with SOX regimen is a first-line treatment for hepatic metastasis of gastric cancer. It can improve the quality of life of patients with gastric cancer and is well tolerated. Key words: Apatinib; S-1; Oxaliplatin; Liver metastases of gastric cancer